Mirae Asset Global Investments Co. Ltd. Sells 16,441 Shares of Catalent, Inc. (NYSE:CTLT)

Mirae Asset Global Investments Co. Ltd. cut its position in shares of Catalent, Inc. (NYSE:CTLT) by 50.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,290 shares of the company’s stock after selling 16,441 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Catalent were worth $732,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Gladius Capital Management LP bought a new position in Catalent during the 3rd quarter worth approximately $28,000. Exchange Traded Concepts LLC bought a new position in Catalent during the 3rd quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC grew its position in Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after acquiring an additional 709 shares during the last quarter. Park Place Capital Corp grew its position in Catalent by 25.2% during the 3rd quarter. Park Place Capital Corp now owns 1,533 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares during the last quarter. Finally, PFG Private Wealth Management LLC bought a new position in Catalent during the 3rd quarter worth approximately $155,000.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CTLT shares. StockNews.com started coverage on Catalent in a report on Friday, April 19th. They issued a “sell” rating for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. Stephens reiterated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. UBS Group reiterated a “neutral” rating and issued a $63.50 price objective (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Finally, Barclays raised their target price on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $52.46.

Catalent Stock Down 0.2 %

Shares of NYSE:CTLT opened at $55.92 on Thursday. The stock has a fifty day simple moving average of $56.78 and a two-hundred day simple moving average of $48.48. The stock has a market capitalization of $10.12 billion, a price-to-earnings ratio of -8.22, a PEG ratio of 6.05 and a beta of 1.20. Catalent, Inc. has a 12-month low of $31.45 and a 12-month high of $60.20. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last posted its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 EPS. On average, research analysts anticipate that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.